| Authors: |
Olivera I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Oncobell Program, Catalan Institute of Cancer (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERESP, Hospitalet de Llobregat, Barcelona, Spain and ARAID Researcher, Aragon Health Research institute (IIS Aragon), Zaragoza, Spain., Bolaños E; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Rodriguez I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Etxeberria I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Cirella A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Egea J; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Garasa S; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Migueliz I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Eguren-Santamaria I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Azpilikueta A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Alvarez M; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Ochoa MC; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Malacrida B; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., Propper D; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., de Andrea CE; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Balkwill FR; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., Teijeira Á; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain. |
